CTOs on the Move

BigHat Biosciences

www.bighatbio.com

 
BigHat`s mission is to improve human health by making it far easier to design advanced, next-generation antibody therapeutics.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

BigHat Biosciences raised $19M on 02/10/2021

Similar Companies

Azurity

Azurity Pharmaceuticals, Inc. is a privately held specialty pharmaceutical company focused on the needs of patients, especially children and the elderly, that require customized user-friendly drug formations. Our products have benefited millions of patients whose needs are not served by other commercially available therapies. AZURITY VALUES: COMPASSION - We put the needs of our patients and caregivers at the center of everything we do, including the decisions we make. QUALITY - We aim to provide our patients with the highest-quality, safe, and effective therapies for their needs. INNOVATION - We use the best science and manufacturing techniques to deliver cost-effective, high-value medications to our patients. A COMPANY OF DIFFERENCE MAKERS As Azurity grows to meet new challenges, and serve new patient groups, one thing never changes: our dedication to the lives of others. Whether through our innovative medications, our focus on creating a positive company environment, or our community and volunteer work, we are committed to having a positive impact on the lives of those we touch.

Harendorf Technolgy

Harendorf Technolgy is a North York, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Compass Health

Compass Health Northwest Washington’s Behavioral Healthcare Leader Access Services Compass Health provides comprehensive services to treat behavioral health…

Cognito Therapeutics

Cognito Therapeutics is a pioneer in non-invasive neuromodulation to treat neurodegenerative diseases and improve human cognitive performance. The company has completed multiple clinical studies demonstrating its investigational therapeutic has the potential to safely slow or stop cognitive decline and loss of brain volume in Alzheimer`s disease. Cognito has received FDA Breakthrough Device Designation for the treatment of Alzheimer`s disease and expects to start pivotal studies in 2022. The company`s technology was based on pioneering optogenetics research by scientific co-founders Professors Li-Huei Tsai and Ed Boyden at MIT.